

Contents

Preface _____	000
----------------------	-----

Keynote Addresses

The Symposium Tradition _____	000
--------------------------------------	-----

Andersen Ø.

The Concept of Targeting _____	000
---------------------------------------	-----

From mythology to modern medicine

Bruland Ø. S.

The Interface Between the Academia and the Industry _____	000
--	-----

New challenges in a changing regulatory environment

Piccart M. J., Straehle C. and Therasse P.

on behalf of the Breast International Group

On the Spoken Word in the Scientific Discourse _____	000
---	-----

Pihl A. and Bruland Ø.S.

Three Simple Questions _____	000
-------------------------------------	-----

Seljelid R.

Knowledge and Evidence _____	000
-------------------------------------	-----

Serck-Hansen C.

Invited Lectures

Lymphangiogenic Growth Factors and Tumor Metastasis _____	000
--	-----

Alitalo K., He Y. and Kärpänen T.

Targeting the Skeleton and Cancer in Bone _____	000
--	-----

Samarium treatment of osteosarcoma, osteoblastic
bone metastases, and neoplastic disease in the bone marrow

Anderson P. M.

The Multistep Nature of Human Cellular Transformation _____	000
--	-----

Ben-Porath I. and Weinberg R. A.

Therapeutic Cancer Vaccines _____	000
<i>Bruck C., Brichard V., Coche T., Gérard C., Guéguen M., Palmantier R. and Tiest W.</i>	
Targeted Therapy for Lung Cancer _____	000
<i>Bunn P. A.</i>	
A Clinical Study of an mTOR Inhibitor CCI-779 in Advanced Breast Cancer _____	000
<i>Chan S.</i>	
Pharmacogenomics and Cancer _____	000
Moving towards targeted therapy and intervention	
<i>Chanock S.</i>	
Targeting the Epidermal Growth Factor Receptor (EGFR) as Cancer Therapy _____	000
<i>Ciardiello F.</i>	
Adoptive Cell Transfer Therapy _____	000
<i>Dudley M. and Rosenberg S. A.</i>	
Design of Drugs Targeting the Cell Cycle _____	000
<i>Garret M. and Workman P.</i>	
COX-2 in Cancer _____	000
A player that's defining the rules	
<i>Hawk E.</i>	
Dissecting Tumor Pathophysiology using Intravital Microscopy _____	000
<i>Jain R. K., Munn L. L. and Fukumura D.</i>	
Gastrointestinal Stromal Tumor _____	000
A solid tumor model for targeted cancer therapy	
<i>Joensuu H.</i>	
Rituximab: Mechanisms of Action in Lymphoma _____	000
<i>Johnson P.</i>	
Cancer Chemoprevention: Targeting Common Abnormalities _____	000
<i>Mao L.</i>	
Imatinib in Chronic Myeloid Leukemia _____	000
<i>O'Brien S. G.</i>	
Herceptin in the Treatment of Breast Cancer _____	000
<i>Piccart M., Mano M., Dolci S., Straehle C. and Cardoso F.</i>	
Radioimmunotherapy of B Cell Lymphomas _____	000
<i>Press O. W.</i>	

Strategies for the Development of Molecularly Targeted Therapeutics _____ 000
Bioinformatics and clinical trial design
Simon R.

Optimizing Immunotoxins Containing Ricin a Chain
Vitetta E. S.

Targeted Irradiation of Brain Tumours _____ 000
Zalutsky M. R., Reardon D. A., Akabani G., Friedman A. H., Friedman H. S. and Bigner D. D.

Proffered Papers

Characterization of Intracellular Mechanisms Responsible for the Cytotoxic Effect of Immunotoxins in Cancer Cells _____ 000
The protein synthesis inhibitor cycloheximide (CHX) sensitized the cells to the immunotoxin treatment
Andersson Y., Juell S., Engebraaten O. and Fodstad, Ø.

Photochemical Internalisation (PCI) _____ 000
A novel technology for targeted macromolecule therapy
Berg K., Prasmickaite L., Selbo P. K., Hellum M., Bonsted A., Engesater B. Ø., Weyergang A. and Hogset A.

Vaccibodies: A Novel Vaccine Strategy for Multiple Myeloma _____ 000
Brunsvik, A., Sandlie, I. and Bogen, B.

Mechanisms of Synergistic Growth-stimulatory Effects _____ 000
EGF receptors, cyclooxygenases and G protein-coupled receptors
Christoffersen T., Guren T. K., Dajani O. F., Nilssen L. S., Ødegård J., Thoresen H. G. and Sandnes D.

Distribution of Therapeutic Macromolecules in Osteosarcoma Xenografts _____ 000
Davies C. de L., Eikenes L., Lundstrøm L. M., Tari M. R., Brekken C., Frengen J., Kaalhus O. and Bruland Ø. S.

Tailoring Anticancer Treatment by Microdialysis and Genotyping.
Ekstrøm P. O. and Giercksky K-E.

Collaboration between Cancer Registries and Pharmaceutical Companies or Companies in Biotechnology _____ 000
Holmberg L., Tryggvadottir L., Langmark F., Storm H. and Hakama M.

Radium Revisited _____ 000
Targeting of skeletal metastases by the alpha-emitter radium-223
Larsen R. H. and Bruland Ø. S.

Targeting P-glycoprotein for Execution of Cellular Death Mechanisms in Cancer _____	000
<i>Lehne G. and Shtil A. A.</i>	
Tumour Selectivity of Photodynamic Therapy _____	000
<i>Moan J., Cunderlikova B., Juzeniene A., Juzenas P., Ma L-W. and Iani V.</i>	
False and Self-fulfilling Paradigms _____	000
Examples from breast cancer research	
<i>Møller P. and Hovig E.</i>	
Patenting Genes _____	000
A synergy or conflict between economics, ethics and culture?	
<i>Møller P. and Vigen T.</i>	
Apoptosis Induction by Radioimmunotherapy _____	000
<i>Stigbrand T., Joniani H. M., Eriksson D., Löfroth P-O., Johansson L. and Åhlström K. R.</i>	
Targeted Treatment of Oral Cancer _____	000
<i>Sudbø J. and Bryne M.</i>	